ELISA 키트 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

ELISA Kit Market

The future of the global elisa kit market looks promising with opportunities in the laboratory, testing institution, and hospital markets. The global elisa kit market is expected to reach an estimated $3.4 billion by 2035 from $2.1 billion in 2027 with a CAGR of 6.5% from 2027 to 2035. The major drivers for this market are the increasing demand for diagnostic testing, the rising prevalence of chronic diseases, and the growing adoption of point-of-care testing.

• Lucintel forecasts that, within the type category, sandwich ELISA is expected to witness higher growth over the forecast period due to higher sensitivity and specificity in antigen detection assays.
• Within the application category, laboratory is expected to witness the highest growth over the forecast period due to increasing diagnostic testing volumes in clinical laboratories.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to expanding diagnostic lab infrastructure in the region.

Emerging Trends in ELISA Kit Market

Shift from routine laboratory testing to faster and more application specific testing. Customer demand are primarily from clinical research, biopharma, food testing, and academic laboratories. Lucintel suggests resulting from reproducibility, advances in automation, regulatory approval, and the capability to meet regional demand.

• Automation: 96-well ELISA formats coupled with robotic liquid handling systems and laboratory information management systems were implemented in many labs in 2025, minimizing pipetting and increasing test automation; this trend is will continue as testing demand increases and a skilled workforce remains scarce.
• Multiplexing: Suppliers are focusing on expanding the principles of conventional ELISA assays to develop multiplex immunoassays which enable simultaneous measurement of several biomarkers from small sample volumes. This will allow significant research time reduction and will find wide application in those laboratories where significant insight into biology is needed, with little or no increase in investment in capital instruments.
• Sustainability: In 2025, buyers began to take into consideration packaging and solvents, cold chain burden, and recyclability as part of assessing an ELISA kit. For the next 3 to 5 years, the environmental sustainability of procurement will have an influence on the design of kits and the selection of suppliers.
• Application Specialization: Focus is now more on the development of specialized assays for specific applications, spawning the development of panels, as opposed to offering open-ended assays. In 2026, emphasis will be on developing assays for validated biomarkers and matrix. This will help improve customer satisfaction and retention.
• Regional Diversification: The risk of supply disruption in 2025-2027 has motivated laboratories to begin sourcing secondary qualified suppliers in North America, Europe, and Asia Pacific, although major global suppliers still enjoy healthy trust; dispersed production minimizes the risk of delivery and fosters quicker local compliance.

Even though the elisa kit market is set to grow steadily, suppliers cannot afford to rely on broad catalogues. Buyers are becoming more discerning towards validated performance, automation, and improved documentation, as well as reliability of delivery. Multiplexing and specialized biomarkers will cater to higher value demand, while emphasis on regional sourcing and sustainability will influence procurement. Competing assays that integrate workflows will likely defend margins most effectively through 2030.

Recent Developments in the ELISA Kit Market

Elisa kit market activity is expected to increase in 2025 through 2027, as funding for research continues to reshape purchasing together with the integration of decentralized diagnostics and multiplex testing. Lucintel anticipates a shift in market demand towards higher analytical sensitivity and applications focused on more customized assay panels in combination with greater automation. Instead of the traditional reliance on higher volume, vendors have allocated their capital toward broader assay offerings, regulatory readiness, and improvements in the resiliency of their manufacturing processes.

• Automation: In January 2025, Thermo Fisher released the KingFisher Apex Dx system, enabling 96 sample processing in a single run. This announcement supports the growing demand for automated ELISA kit workflows. Laboratory automation is anticipated to be a defining trend in laboratory automation for the next three to five years.
• Multiplex: In March 2025, Bio-Techne launched new Ella immunoassay menus offering panels with the ability to measure several biomarkers with minimal sample volumes. This will likely drive markets to purchase more integrated panels and will influence hospitals and research laboratories to purchase more panels when the cost is justified by clinical relevance.
• Regulatory: Suppliers of in vitro diagnostics (IVDs) in Europe continued preparations in the IVDR (In Vitro Diagnostic Regulation), with a deadline extension for conformity of some legacy IVDs set for December 2027 (January 2025). This will drive the market toward more rationalized offerings, and will favor suppliers with documented performance and improved quality systems.
• Production Investment: Danaher forecasted 2024 revenue to be around $24.5 billion, as it made capacity and technology investments across life science businesses (February 2025). With larger suppliers, regional manufacturing, inventory buffers, and valuation programs get more difficult for smaller kit makers.
• Strategic Partnerships: The 2025 WHO Diagnostic Priorities continued to focus on affordable immunoassays for infectious disease surveillance (February 2025). Collaborations between public laboratories and kit manufacturers will provide greater access to the market, especially in regions where centralized molecular testing is either prohibitively extensive or difficult to sustain.

Market disruptions will continue to occur. Greater adoption will occur in the research-use space, specifically in immunology, oncology, and biopharma, but clinical adoption will hinge on hurdles in the IVDR framework and reimbursement. More and more buyers want to see validated automation for use on lot-to-lot consistent assays with reduced turnaround times. Suppliers who can adequately focus menus and deliver regionally consistent kits will gain market share. Expanding undifferentiated catalogs will not gain much market share.

Strategic Growth Opportunities in the ELISA Kit Market

From now until 2026, the market for elisa kit market will move from routine research towards more specialized clinical research, more rapid research, more complex, and higher specific tests and assays as well as more varieties of decentralized testing. Funding for biomarker discovery, higher prevalence of chronic diseases, and tighter demands for productivity of lab work, will provide increased competition in the market. Lucintel predicts that suppliers that combine high performance assays with large scale distribution will gain market share.

• High Sensitivity, Multiplex Assays: Several assays that take multiple measurements from few samples are proving to be popular. In January 2025, Quanterix indicated that their Simoa platform reached femtomolar sensitivity for a number of assays. Purchasing will be influenced by the ability to make earlier diagnoses with less sample and technician time.
• Expansion in Clinical Diagnostics: There is a larger potential market for clinical grade ELISA kits used to diagnose and manage chronic diseases and other disorders when compared to RUO kits. In March 2025, the FDA catalogued over 6,000 IVDs that have received regulatory clearance. Suppliers capable of making validated clinical kits have the potential to meet the demand for assays used in clinical diagnostics for the next three to five years.
• BioPharmaceutical Quality Control: Reliable kits for host cell proteins, DNA, endotoxins, and process related impurities are needed by organizations that conduct contract manufacturing for biopharmaceuticals. In February 2025, the FDA documented more than 20,000 active biologics applications. Contract manufacturers will continue to create a sustained demand for assays that meet all regulatory requirements.
• Supply Chain Throughout Emerging Markets: Local technical support along with smaller pack sizes can promote adoption of products in India, Southeast Asia, Latin America, and Africa. The Indian pharmaceutical market showed annual growth of over 8% in April, 2025. By developing regional partnerships, we can address import challenges and offer dedicated ELISA portfolio channels.
• Digitization of Assay Workflows: Increased switching costs can come from cloud-connected readers and automated plate handling along with software-based results. Thermo Fisher had approximately $42.9 billion of annual revenue in May, 2025, showing the scale of integrated laboratory systems. Through workflow automation, customers may become more inclined to purchase integrated kit offerings over isolated reagent offerings.

Commercially successful offerings will not be determined exclusively on catalog breadth. Companies must provide evidence on reproducibility, regulatory compliance, and total cost per result. Shortened adoption cycles result from regional partnerships with hospitals, contract research organizations, and distributors. Though market conditions will remain competitive and price pressures will persist, high volumes of testing will allow companies to maintain margin if their solutions are efficient and reliable and have higher levels of automation.

ELISA Kit Market Drivers and Challenges

Progress in technology, evolving demands for diagnostics, Economic conditions, regulations and Expectations of sustainability affect the elisa kit market. Modern diagnostics, advanced customized medicines, research, and decentralized testing provide market opportunities while the complex approvals process, constraints of the supply chain and limitations of reimbursement slow market growth. Innovation, automation and the growing trend of providing healthcare to a greater number of people are key forces Lucintel considers in competition and in the development of the market in the long term.

The factors responsible for driving this market include:

• The Growing Demand for Diagnostics: The impact of the increased testing for cancer biomarkers, autoimmune disorders, chronic conditions, and infectious diseases on the proliferation of ELISA has been significant. In January 2025, the World Health Organization published statistics reporting that noncommunicable diseases accounted for an estimated 41 million annual deaths. The next 3 to 5 years will see increased preventive care, resulting in greater demand for quality ELISA kits among hospitals, labs, and public health programs.
• Industry Trends: Automation and improvements in the field of biotechnology coupled with AI technology are improving the speed and accuracy of diagnostic testing. In March 2025, laboratory automation platforms that were able to process 300 microplate tests in one hour illustrated the high degree of throughput that is available to modern high-volume labs. The advances will enable the industry to achieve the goal of ELISA kits that are better suited for centralized and decentralized clinical testing.
• Research and Personalized Medicine: Research and development of personalized medicine, biomarker discovery, pharmaceutical research, and vaccine development rely on sensitive measurements of proteins and antibodies. In June 2025, the global clinical trials activity exceeded 20,000 actively recruiting studies, enabling sustained demand for standardized immunoassays. Over the next three to five years, increase in biologics and personalized medicine will create greater demand for ELISA kits to be used in translational research, development of companion diagnostics, and therapeutic monitoring.
• Regulatory and Public-Health Support: Validated diagnostic technologies become more prevalent due to government screening programs, increased urgency in regulatory systems, and higher quality standards in laboratory services. In February 2025, the laboratory control systems in many areas continued requiring documented assay performance and quality control. The next three to five years will emphasize traceable reagents, robust documentation, and reliable results, as well as compatibility with accredited laboratory workflows.
• Manufacturing Efficiency and Sustainability: Higher sustainability and lower cost have put an emphasis on design to minimize waste through better reagent stabilization, different formats that use less material, more bulk production, and packaging that can be easily recycled. In April 2025, many of the high throughput clinical labs reported using a standardized microplate format that was 96 wells, enabling multiple tests to be done in parallel. This infrastructure will enable growth in the marketplace due to improved overall efficiency, product affordability, extended shelf life, reduced resource usage, and extended use in less developed healthcare and research markets.

The challenges facing this market include:

• Elaborate Regulatory Frameworks: ELISA kits meant for clinical use must undergo demanding validation and performance criteria that have country specific variations in the requirements for quality and labeling. Regulatory submissions for many In-vitro diagnostic kits in May 2025 required thorough analytical and clinical evidence for several performance metrics. From now until the next few years, the complexity of the regulatory framework is likely to create barriers to market entry for small players, while increasing the time and cost of compliance for all players.
• Supply Chain and Cost Pressures: ELISA manufacturers are at risk due to the use of antibodies, enzymes, chemicals, and plastic covering that need cold chain transport. In July, some routes of international transport had freight costs that were at least 20 percent greater than what they were before the disruption. These price indicators affect all consumables and reagents that need cold chain transport. In the coming years, manufacturers will opt for more regional sourcing, longer inventories, more suppliers, and more stable products that need less cold chain transport.
• Competition from Alternative and Emerging Technologies: Competitors to traditional ELISA-based assays include chemiluminescence, lateral-flow assays, molecular assays, and mass spectrometry and sequencing. In August, some competing rapid molecular tests were able to improve the time from sample to result to under 1 hour, thereby disrupting the current batch based workflow. In the coming years, ELISA manufacturers will be challenged to design and build rapid, automated, multiplexed, and less expensive assay platforms for high throughput.

The increasing demand for diagnostics and the barriers for innovation in biomedical research, automation, and personalized medicine will, without a doubt, create a growing need for elisa kits. Even with the recent advancements in technology and automation, elisa kits will not be as cost effective and accessible until significant improvements in manufacturing are made. While emerging technologies may help streamline the elisa kit manufacturing process, the myriad of associated regulations will make it difficult for growth to be sustained. Focus will likely be on the integration of automation into the manufacturing process, while also focusing on regional supply chains to support continuous and sustainable production. The elisa kit market will continue to rely on improving cost-effectiveness and accessibility, in addition to technological advances that improve their dependability, while adhering to regulations and easing their adoption into various markets and healthcare systems around the world.

List of ELISA Kit Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies elisa kit market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the elisa kit market companies profiled in this report include-

• Thermo Fisher Scientific
• Enzo Life Sciences
• BioLegend
• Merck
• Bio-Techne
• BD Biosciences
• Bio-Rad Laboratories
• Aviva Systems Biology
• Repligen
• Lifespan Biosciences

ELISA Kit Market by Segment

The study includes a forecast for the global elisa kit market by type, application, and region.

ELISA Kit Market by Type [Value ($B) from 2019 to 2035]:

• Indirect ELISA
• Sandwich ELISA
• Competitive ELISA
• Others

ELISA Kit Market by Application [Value ($B) from 2019 to 2035]:

• Laboratory
• Testing Institutions
• Hospital
• Others

ELISA Kit Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the ELISA Kit Market

During 2025- 2027, the elisa kit market is expected to enter a policy-led investment cycle as governments are expected to focus on biological preparedness and sovereignty of domestic diagnostics and research during this period. According to Lucintel's latest market report, government spending and localization of manufacturing will reshape procurement and supply chain decisions in major economies during this period.

• United States: During this period, the US government is likely to continue to prioritize federal research and domestic biomanufacturing support. The NIH allocated almost USD 48.5 billion in 2025 (March 2025) and continues to sustain the demand for validated ELISA workflows in pharmaceutical, academic and public health testing through the existing capacity and research efforts. Additionally, Thermo Fisher Scientific continues to implement its previously announced multibillion-dollar investment in domestic manufacturing in the US.
• China: During this period, it is anticipated that China will continue to support domestic biotechnology as indicated in the 2025 Government Work Report which indicated a 10% increase in government research funding (March 2025). These policies will drive increased procurement and manufacturing of diagnostics, and, in turn, will increase the domestic supply of ELISA kits and reduce dependence on imported supplies over the next 3 to 5 years.
• Germany: In March 2025, Germany announced a €500 billion special infrastructure fund, coupled with amended fiscal rules. While not dedicated to diagnostics, the package supports research infrastructure and industrial resilience, as well as digital laboratories. EU-level procurement maintains a preference for quality-assured suppliers. The package creates an attractive investment climate for higher-throughput assay production and lab modernization.
• India: The 2025 Union Budget included a ₹1 trillion research, development, and innovation financing mechanism, in addition to ongoing biotechnology manufacturing incentives. Public and private funding should allow Indian companies to source antibodies and reagents and develop test kit platforms. This would enable greater domestic production of test kits, which would enhance continuity and broaden institutional use of ELISA testing.
• Japan: The 2025 Japanese budget approximately ¥115.5 trillion retained significant allocations for health, science, and aging infrastructure. National spending on precision medicine and laboratory automation corresponds with initiatives undertaken by Japanese diagnostics companies. This should promote the use of higher-throughput, locally adopted ELISA systems in the medium term.

Features of the Global ELISA Kit Market

• Market Size Estimates: elisa kit market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: elisa kit market size by type, application, and region in terms of value ($B).
• Regional Analysis: elisa kit market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the elisa kit market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the elisa kit market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the elisa kit market by type (indirect ELISA, sandwich ELISA, competitive ELISA, and others), application (laboratory, testing institutions, hospital, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global ELISA Kit Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Indirect ELISA : Trends and Forecast 2019 to 2035
• 4.4 Sandwich ELISA : Trends and Forecast 2019 to 2035
• 4.5 Competitive ELISA : Trends and Forecast 2019 to 2035
• 4.6 Others : Trends and Forecast 2019 to 2035

5. Global ELISA Kit Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Laboratory : Trends and Forecast 2019 to 2035
• 5.4 Testing Institutions : Trends and Forecast 2019 to 2035
• 5.5 Hospital : Trends and Forecast 2019 to 2035
• 5.6 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global ELISA Kit Market by Region

7. North American ELISA Kit Market

• 7.1 Overview
• 7.2 North American ELISA Kit Market by Type
• 7.3 North American ELISA Kit Market by Application
• 7.4 The United States ELISA Kit Market
• 7.5 Canadian ELISA Kit Market
• 7.6 Mexican ELISA Kit Market

8. European ELISA Kit Market

• 8.1 Overview
• 8.2 European ELISA Kit Market by Type
• 8.3 European ELISA Kit Market by Application
• 8.4 German ELISA Kit Market
• 8.5 French ELISA Kit Market
• 8.6 Italian ELISA Kit Market
• 8.7 Spanish ELISA Kit Market
• 8.8 The United Kingdom ELISA Kit Market

9. APAC ELISA Kit Market

• 9.1 Overview
• 9.2 APAC ELISA Kit Market by Type
• 9.3 APAC ELISA Kit Market by Application
• 9.4 Chinese ELISA Kit Market
• 9.5 Indian ELISA Kit Market
• 9.6 Japanese ELISA Kit Market
• 9.7 South Korean ELISA Kit Market
• 9.8 Indonesian ELISA Kit Market

10. ROW ELISA Kit Market

• 10.1 Overview
• 10.2 ROW ELISA Kit Market by Type
• 10.3 ROW ELISA Kit Market by Application
• 10.4 Middle Eastern ELISA Kit Market
• 10.5 South American ELISA Kit Market
• 10.6 African ELISA Kit Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global ELISA Kit Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Thermo Fisher Scientific
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Enzo Life Sciences
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 BioLegend
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Merck
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Bio-Techne
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 BD Biosciences
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Bio-Rad Laboratories
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Aviva Systems Biology
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Repligen
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Lifespan Biosciences
  • Company Overview
  • ELISA Kit Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us